Leerink Partners analyst David Risinger has maintained their bullish stance on JNJ stock, giving a Buy rating yesterday.
David Risinger has given his Buy rating due to a combination of factors, despite the recent legal challenges faced by Johnson & Johnson. The dismissal of JNJ’s Red River talc bankruptcy plan by a Texas judge highlights ongoing litigation issues, but these legal hurdles have not deterred the company’s overall financial health. The rejected $8 billion settlement is relatively small compared to JNJ’s market cap of $400 billion, indicating that the financial impact may be limited.
Additionally, Johnson & Johnson has reaffirmed its growth projections, expecting an operational sales compound annual growth rate (CAGR) of 5-7% from 2025 to 2030. This positive outlook on future sales growth supports the Buy rating, as it suggests the company is well-positioned for long-term success. Risinger’s analysis likely considers both the resilience of JNJ’s business model and its potential for continued expansion, despite current legal challenges.
In another report released yesterday, UBS also reiterated a Buy rating on the stock with a $180.00 price target.
JNJ’s price has also changed slightly for the past six months – from $162.060 to $165.840, which is a 2.33% increase.